ABSTRACT
La linfocina conocida como interferón (IFN) existe en tres tipos principales (-Ó, -ß y -ç), cada uno de ellos con diferente capacidad como agente antiviral, antitumoral o como inmunomodulador, esta características motivaron su aplicción exógena desde su descubrimiento como terapia para el tratamiento de diversos padecimientos, esto sin embargo, trajo consigo severos efectos colaterales del IFN exógeno, y de estimular la síntesis endógena en el organismo para aprovechar sus propiedades en la eliminación de alguna enfermedad (viral, tumoral, etc.), se han probado una enorme cantidad de compuestos, tanto de origen natural como sintético (inductores), lamentablemente hasta el momento no se ha encontrado al inductor idóneo, debido principalmente a factores, como: el tipo y grado de la infección o proceso tumoral, población estudiada, toxicidad de la molécula, etc., por estos motivos son necesarios la realización de un mayor número de trabajos para encontrar al mejor inductor, capaz de utilizarse con fines terapéuticos y que además muestre un mínimo de efectos secundarios al paciente al cual se aplique. En el presente trabajo se revisan algunos estudios que hablan de la utilidad, así como de los efectos secundarios de los inductores de la síntesis de IFN como el polyA:polyU, el PolyI:polyC, PolyI:polyC12U, Ridostine, Bropirimine y de un ARNt de orgien fúngico utilizados en el tratamiento de procesos infecciosos y tumorales
Subject(s)
Humans , Animals , Mice , Antiviral Agents , Communicable Diseases/therapy , Interferon Inducers/therapeutic use , Lymphokines , Primates , RNA, TransferABSTRACT
Objetivo: Descrever um caso de hemangioendotelioma kaposiforme, único tumor malígno de origem vascular específico da infância. Métodos: Relata-se o caso de lactente do sexo feminino com 40 dias de vida que apresentava um hemagioma gigante da face. O tumor evoluiu com crescimento rápido levando à compressäo da laringe com insuficiência grave. A criança tinha ainda uma coagulopatia trombocitopênica de consumo (síndrome de Kasabach-Merritt). Resultados: Ela foi admitica à UTI Pediátrica do Hospital das Clínicas da Universidade Estadual de Campinas e foi iniciada ventilaçäo mecânica. O tratamento durante dez dias com dexametasona levou à melhora por curto período. Foi inciado interferon alfa-2a na dose de 1,8 milhöes de unidades/m²/dia por via subcutânea, porém a paciente foi à óbito 4 dias após o início dessa terapia. A necrópcia revelou o diagnóstico de um hemangioendotelioma kapasiforme. Conclusäo: Discutem-se a evoluçäo fatal pouco freqüente de um hemangioma gigante e suas complicaçöes hematológicas.
Subject(s)
Humans , Female , Infant , Hemangioendothelioma/therapy , Hemangioma/therapy , Adrenal Cortex Hormones/therapeutic use , Dexamethasone/therapeutic use , Intensive Care Units , Interferon Inducers/therapeutic use , Respiration, ArtificialABSTRACT
The efficacy of the interferon stimulator named Stronger Neo Minophagen-C (SNMC) derived form the plant G. glabra was studied at a dose of 40 or 100 ml daily for 30 days followed by thrice weekly intravenously for 8 wk in 18 patients of subacute hepatic failure due to viral hepatitis. The survival rate amongst these patients was 72.2 per cent, as compared to the earlier reported rate of 31.1 per cent in 98 patients who received supportive therapy (P < 0.01). Death in four of the five patients was due to associated infections leading to hepatorenal failure and terminal coma. Further studies are necessary to standardize the dose and duration of therapy with SNMC in subacute hepatic failure.
Subject(s)
Adolescent , Adult , Cysteine/therapeutic use , Drug Combinations , Female , Glycine/therapeutic use , Glycyrrhiza/chemistry , Humans , Interferon Inducers/therapeutic use , Liver Failure/drug therapy , Male , Middle Aged , Oleanolic Acid/analogs & derivatives , Plants, MedicinalABSTRACT
6-MFA, an extract from the fungus Aspergillus ochraceus was administered to 8 bonnet macaques. An equal number of monkeys matched for age, sex and weight received placebo and served as controls. Twenty hours after the administration of the 6-MFA/placebo the monkeys were challenged with an Indian strain of Japanese encephalitis virus by the intranasal route. Signs and symptoms of the disease such as fever, tremors, loss of appetite, dehydration, flaccid paraplegia or quadriplegia were pronounced in all the control monkeys, while in the 6-MFA treated group only two developed symptoms. Virus could be isolated from only one of the 6-MFA treated monkeys on day 6, and from four control monkeys; one each from CSF, spinal cord, blood and from both nasal swab and blood of the fourth monkey. The appearance of HI and N antibodies in 6-MFA treated group was either delayed or completely suppressed. The results indicate that 6-MFA is a potential antiviral agent which can be used to reduce the morbidity and mortality in bonnet macaques (Macaca radiata) experimentally infected with Japanese encephalitis virus.